SOSAFE
SoSafe, Europe’s largest security awareness and human risk management vendor, has appointed four new Executive Advisors. The advisors, comprised of industry experts and technology investors, will provide advice and strategic counsel to the SoSafe leadership team on its ambitious plans to expand their category and product leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529386435/en/
New hires Ilona Simpson, Carsten Thoma, Christian Karam, Sean Catlett (Photo: Business Wire)
With Forrester predicting that 90% of data breaches in 2024 will involve the human element, reducing human risk is what organisations need to prioritize for business continuity. SoSafe offers a technology-driven solution based on psychology and human-centric design. While SoSafe is committed to empowering digital self-defence around the world, the company is currently leading the category evolution from security awareness and training to human risk management. The Executive Advisors will support this transformative process from both an industry and organisational perspective to increase the company's speed to scale.
The following Executive Advisors will join:
Sean Catlett: Sean is the Chief Information Security and Trust Officer at Bumble. He also served as the Chief Security Officer at Slack, and as Chief Information Security Officer at Reddit and is an advisor to Balance Theory and Hampton North.
"It is clear that cybercriminals are effective at focusing on the human layer of security. AI-powered tools offer them solutions that scale attack success rates, intensifying cyber threats, and I believe the full potential is yet to be seen. We need comprehensive and effective solutions that counter these rising threats by sustainably empowering a strong security culture and reducing human risk - and SoSafe delivers just that in a new and innovative way", states Sean Catlett.
Christian Karam: Christian is an investor and senior advisor on technology investments, previously serving as the Deputy Group Chief Information Security Officer at UBS and the Head of Research & Innovation at INTERPOL.
“Cybercriminals continue to innovate rapidly, outpacing many organisations’ ability to keep up. Mere compliance training videos are no longer enough to overcome this challenge. We must rethink security awareness by building effective and robust security cultures that embrace continuous learning and treat mistakes as key drivers of resilience. SoSafe is leading this transformation towards holistic, people-centric human risk management, and I look forward to contributing to this journey”, says Christian Karam.
Ilona Simpson: Ilona is a trained psychologist and a long-standing CIO across a range of industries and companies, having worked at Netskope, adidas, EON, Aston Martin, DHL, and Porsche.
"We've made a lot of progress over the last few years in terms of the attention that senior management and boards are giving to the human layer of cybersecurity. For CIOs, the human factor and reducing human risk is top of mind. Now, they need effective and simple solutions to help them reduce human risk in a sustainable way”, states Ilona Simpson.
Carsten Thoma: Carsten is the President of Celonis. He has co-founded and scaled Hybris, sold to SAP and became President of SAP CX and member of the Global Executive Team. He serves as an advisor to La Famiglia/General Catalyst, and has been a long-standing investor and entrepreneur.
"SoSafe has the most promising foundation a young company can have: They are solving one of the most important business problems of our time in a fundamentally different way than their competitors. It's my ambition to help them succeed and, together with SoSafe's leadership team, build a global champion from Europe”, states Carsten Thoma.
“We are very honoured that some of the best minds in business and technology have agreed to serve as critical advisors to SoSafe. At this pivotal time in our development, their expertise will enable us to grow even faster, smarter, and more focused. I know I speak for the rest of the executive team when I say that we will value their experienced counsel as we look to accelerate our growth as a company”, states Dr Niklas Hellemann, Psychologist and CEO at SoSafe.
About SoSafe
SoSafe, founded by a team of behavioural scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioural science, SoSafe enhances secure behaviour across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defence by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529386435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
